Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01435122 · ClinicalTrials.gov registry record · Phase 2
A Study of Axitinib in Advanced Carcinoid Tumors
A Phase 2 study of Carcinoid Tumor, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT01435122: Completed Phase 2 study of Carcinoid Tumor, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT01435122 is a Phase 2 study of Carcinoid Tumor that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 30 participants, below the 95-participant average among 8 other Carcinoid Tumor trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01435122, a Phase 2 study of Carcinoid Tumor, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main purpose of this study is to see whether Axitinib will help prolong the time that the patient's carcinoid tumors remain stable, and to examine their treatment response through testing. Researchers also want to find out if Axitinib is safe and tolerable.
Primary Outcome
Progression-free survival rate at 12 months. PFS: determined as the time from administration of the initial dose of axitinib until objective tumor progression using Response Evaluation Criteria In Solid Tumors (RECIST), or death. Progressive Disease (PD) Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single
Conditions Studied
Interventions
- DRUG Axitinib
Study Locations (2)
California
- University of California San Francisco (UCSF) - San Francisco
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-10-25 |
| Est. Completion | 2018-02-13 |
| Phase | Phase 2 |
What the finished NCT01435122 record still lists
NCT01435122 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 95-participant average among 8 other Carcinoid Tumor trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Carcinoid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Axitinib is the first listed.
NCT01435122 reports a single indexed study location in California, Florida.
Frequently Asked Questions
What is clinical trial NCT01435122 about?
NCT01435122 is a clinical study titled "A Study of Axitinib in Advanced Carcinoid Tumors". The main purpose of this study is to see whether Axitinib will help prolong the time that the patient's carcinoid tumors remain stable, and to examine their treatment response through testing. Researchers also want to find out if Axitinib is safe and tolerable.
What is the current status of trial NCT01435122?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2011-10-25. Estimated completion is 2018-02-13.
What conditions does trial NCT01435122 study?
This clinical trial studies the following conditions: Carcinoid Tumor.
What interventions are being tested in trial NCT01435122?
The interventions under investigation include: Axitinib (DRUG).
Who is sponsoring clinical trial NCT01435122?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01435122 being conducted?
This trial has 2 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01435122's enrollment target sits among peer trials
30 8th of 8 higher than 1 of 8 other Carcinoid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
-
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
COMPLETED · Phase 2
-
A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors
COMPLETED · Phase 2
-
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI